Alfasigma Acquires Intercept Pharmaceuticals
Alfasigma S.p.A announced on September 25 that it acquired Intercept Pharmaceuticals for more than $793.87 million. According to data captured in the LevinPro HC database, this transaction represents the 81st Pharmaceutical acquisition of the year. Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis and severe alcohol-associated hepatitis. The company announced revenues of $285.71 million for the full year ending on December 31, 2022. One of Intercept’s lead products is Ocaliva®, which is the only FDA-approved... Read More »
Murphy Canyon Acquisition Corp. Merges with Conduit Pharmaceuticals
Murphy Canyon Acquisition Corp. (MURF) announced on September 22 the completion of its previously announced merger with Conduit Pharmaceuticals Inc. for a pro forma enterprise value of approximately $720 million. According to data captured in the LevinPro HC database, this transaction represents the 79th Pharmaceuticals transaction of the year. Conduit is a disease agnostic life science company providing an efficient model for compound development. Conduit acquires assets that are Phase II-ready and then seeks an exit through third-party license deals following successful clinical trials. Led by a team of pharmaceutical executives, it was established to fund the development of... Read More »
Pharmanovia Acquires CNS Portfolio From Sanofi
Pharmanovia announced on September 18 the expansion of its neurology portfolio with the acquisition of 11 central nervous system (CNS) brands from global healthcare company, Sanofi. According to data captured in the LevinPro HC database, this transaction is the 75th Pharmaceutical acquisition of 2023. Sanofi is selling a portfolio of CNS brands, including Frisium®, Sentil®, Urbanyl®, Urbanil®, Urbanol®, Urbadan®, Noiafren®, Castilium®, Gardenal®, Tercian® and Stemetil®. The brands span four therapy areas of ongoing unmet need associated with CNS disorders – psycholeptic, anxiolytic, anti-epileptic and anti-psychotic. Pharmanovia (formerly known as Atnahs Pharma UK Limited) is a... Read More »
Waud Capital Partners Launches PharmAlliance Holdings
Waud Capital Partners, a growth-oriented middle market private equity firm based in Chicago, announced on September 14 that it launched PharmAlliance Holdings, LLC. This was done in partnership with Mark Bouck, who will serve as Chief Executive Officer of the platform. PharmAlliance Holdings is a diversified pharmaceutical and life sciences services provider focused on discovery, development and commercialization solutions. Its services span across the drug life cycle for pharmaceutical, biotechnology, life sciences and medical device companies. In conjunction with its launch, PharmAlliance invested in BioBridges, a drug development consulting business serving... Read More »
Nestlé Divests Peanut Allergy Brand to Stallergenes Greer
Nestlé Health Science announced on September 5 its divestment of Palforzia, a children’s peanut allergy drug, to Stallergenes Greer International AG. According to data captured in the LevinPro HC database, this transaction represents the 77th Pharmaceuticals acquisition of 2023. Palforzia became the first drug approved by the FDA for peanut allergy in children in January 2020. At the time, it was projected that the drug could reach $1.28 billion in sales by 2024. Backed by B-FLEXION, Stallergenes Greer International AG is a global biopharmaceutical company. It is based in Baar, Switzerland and specializes in the diagnosis and treatment of respiratory allergies through... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
